Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 4 clinical trials
A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Universitaetsklinikum Erlangen /ID# 214196
 (8.7 away) Contact site
  • 28 Oct, 2020
  • +41 other locations
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)

Histone deacetylase inhibitors (HDACi) like LBH589 have recently been established as novel potent anti-cancer agents for solid and hematologic malignancies. Several pre-clinical reports have shown a good anti-tumoral activity of different HDACi on human or murine HCC models. These compounds, e.g. Trichostatin A, SAHA, MS-275 and others, have been shown …

neutrophil count
percutaneous ethanol injection
radiofrequency ablation
Department of Medicine 1, University Hospital Erlangen
 (8.7 away) Contact site
  • 07 Nov, 2020
  • 1 location
IKKb-matured RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma

A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal melanoma not cureable with local therapy and needing systemic therapy. IKKb-matured Dendritic Cells loaded with autologous tumor-RNA + RNA coding for defined antigens and driver mutations will be added to a standard therapy chosen by the tumor …

University Hospital Erlangen Dept. of Dermatology
 (8.7 away) Contact site
  • 12 Nov, 2020
  • 1 location
Study of Intratumoral CV8102 in cMEL cSCC hnSCC and ACC

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

non-melanoma skin cancer
head and neck carcinoma
squamous cell carcinoma of the head and neck
squamous cell carcinoma
Investigative Site
 (9.4 away) Contact site
  • 07 May, 2020
  • +22 other locations